Nederland - nederlandsk - CBG-MEB (College ter Beoordeling van Geneesmiddelen)

teva nederland b.v. - imipraminehydrochloride samenstelling overeenkomend met; imipramine; - omhulde tablet - imipramine

Nederland - nederlandsk - CBG-MEB (College ter Beoordeling van Geneesmiddelen)

teva nederland b.v. - imipraminehydrochloride samenstelling overeenkomend met; imipramine; - omhulde tablet - imipramine

USA - engelsk - NLM (National Library of Medicine)

bryant ranch prepack - imipramine hydrochloride (unii: bke5q1j60u) (imipramine - unii:ogg85sx4e4) - imipramine hydrochloride 25 mg - for the relief of symptoms of depression. endogenous depression is more likely to be alleviated than other depressive states. one to three weeks of treatment may be needed before optimal therapeutic effects are evident. may be useful as temporary adjunctive therapy in reducing enuresis in children aged 6 years and older, after possible organic causes have been excluded by appropriate tests. in patients having daytime symptoms of frequency and urgency, examination should include voiding cystourethrography and cystoscopy, as necessary. the effectiveness of treatment may decrease with continued drug administration. the concomitant use of monoamine oxidase inhibiting compounds is contraindicated. hyperpyretic crises or severe convulsive seizures may occur in patients receiving such combinations. the potentiation of adverse effects can be serious, or even fatal. when it is desired to substitute imipramine hydrochloride tablets in patients receiving a monoamine oxidase inhibitor, as long an interval should elapse a

Nederland - nederlandsk - CBG-MEB (College ter Beoordeling van Geneesmiddelen)

centrafarm b.v. - imipraminehydrochloride samenstelling overeenkomend met ; imipramine - omhulde tablet - arabische gom (e 414) ; calciumcarbonaat (e 170) ; cellulose, microkristallijn (e 460) ; erythrosine (e 127) ; hypromellose (e 464) ; ijzeroxide geel (e 172) ; ijzeroxide rood (e 172) ; lactose 1-water ; macrogolglycerolricinoleaat ; magnesiumstearaat (e 470b) ; maÏszetmeel ; methylparahydroxybenzoaat (e 218) ; montaanglycolwas (e 912) ; natriumbenzoaat (e 211) ; povidon k 25 (e 1201) ; propyleenglycol (e 1520) ; saccharose ; siliciumdioxide (e 551) ; talk (e 553 b) ; titaandioxide (e 171), - imipramine

USA - engelsk - NLM (National Library of Medicine)

sun pharmaceutical industries, inc. - imipramine hydrochloride (unii: bke5q1j60u) (imipramine - unii:ogg85sx4e4) - imipramine hydrochloride 10 mg - depression - for the relief of symptoms of depression. endogenous depression is more likely to be alleviated than other depressive states. one to three weeks of treatment may be needed before optimal therapeutic effects are evident. childhood enuresis - may be useful as temporary adjunctive therapy in reducing enuresis in children aged 6 years and older, after possible organic causes have been excluded by appropriate tests. in patients having daytime symptoms of frequency and urgency, examination should include voiding cystourethrography and cystoscopy, as necessary. the effectiveness of treatment may decrease with continued drug administration. the concomitant use of monoamine oxidase inhibiting compounds is contraindicated. hyperpyretic crises or severe convulsive seizures may occur in patients receiving such combinations. the potentiation of adverse effects can be serious, or even fatal. when it is desired to substitute imipramine hydrochloride in patients receiving a monoamine oxidase inhibitor, as long

USA - engelsk - NLM (National Library of Medicine)

richmond pharmaceuticals, inc. - imipramine hydrochloride (unii: bke5q1j60u) (imipramine - unii:ogg85sx4e4) - imipramine hydrochloride 10 mg - depression - for the relief of symptoms of depression. endogenous depression is more likely to be alleviated than other depressive states. one to three weeks of treatment may be needed before optimal therapeutic effects are evident. childhood enuresis - may be useful as temporary adjunctive therapy in reducing enuresis in children aged 6 years and older, after possible organic causes have been excluded by appropriate tests. in patients having daytime symptoms of frequency and urgency, examination should include voiding cystourethrography and cystoscopy, as necessary. the effectiveness of treatment may decrease with continued drug administration. the concomitant use of monoamine oxidase inhibiting compounds is contraindicated. hyperpyretic crises or severe convulsive seizures may occur in patients receiving such combinations. the potentiation of adverse effects can be serious, or even fatal. when it is desired to substitute imipramine hydrochloride in patients receiving a monoamine oxidase inhibitor, as long

Canada - fransk - Health Canada

nu-pharm inc - trimipramine (maléate de trimipramine) - comprimé - 12.5mg - trimipramine (maléate de trimipramine) 12.5mg - tricyclics and other norepinephrine-reuptake inhibitors

Canada - fransk - Health Canada

nu-pharm inc - trimipramine (maléate de trimipramine) - comprimé - 100mg - trimipramine (maléate de trimipramine) 100mg - tricyclics and other norepinephrine-reuptake inhibitors

Canada - fransk - Health Canada

nu-pharm inc - trimipramine (maléate de trimipramine) - comprimé - 50mg - trimipramine (maléate de trimipramine) 50mg - tricyclics and other norepinephrine-reuptake inhibitors

Canada - fransk - Health Canada

nu-pharm inc - trimipramine (maléate de trimipramine) - comprimé - 25mg - trimipramine (maléate de trimipramine) 25mg - tricyclics and other norepinephrine-reuptake inhibitors